Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 24, 2003
Event: Acquisition of assets and liabilities related to the one-dimensional electrophoresis business of Amersham Biosciences (SF) Corp., including the Hoefer brand name.
Key Financial Metrics
Transaction Value: Approximately $5.3 million in cash.
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes
The primary material change is the expansion of the company's product portfolio through the acquisition of the Hoefer one-dimensional electrophoresis business. This transaction involves an immediate cash outflow of approximately $5.3 million.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a press release (Exhibit 99.1) detailing the acquisition.
Risks and Uncertainties: The report contains forward-looking statements subject to known and unknown risks. Actual results may differ materially from anticipated results. Specific risk factors are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2002.
Pro Forma Information: Not applicable; no pro forma financial information was provided in this filing.
Investor Verification Checklist
- Verify the exact cash outflow of $5.3 million against the company's current liquidity position.
- Review the attached press release (Exhibit 99.1) for strategic rationale and integration plans.
- Consult the Form 10-K for the year ended December 31, 2002, for detailed risk factors affecting future operating results.
- Confirm the specific assets and liabilities assumed from Amersham Biosciences (SF) Corp.